| mRNA |
Bortezomib |
gCSI |
pan-cancer |
AAC |
0.0096 |
0.9 |
| mRNA |
CIL70 |
CTRPv2 |
pan-cancer |
AAC |
-0.0088 |
0.9 |
| mRNA |
B02 |
CTRPv2 |
pan-cancer |
AAC |
0.0062 |
0.9 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0061 |
0.9 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0057 |
0.9 |
| mRNA |
epigallocatechin-3-monogallate |
CTRPv2 |
pan-cancer |
AAC |
0.006 |
0.9 |
| mRNA |
BRD-K37390332 |
CTRPv2 |
pan-cancer |
AAC |
-0.0065 |
0.9 |
| mRNA |
Bexarotene |
GDSC1000 |
pan-cancer |
AAC |
-0.0056 |
0.9 |
| mRNA |
Nilotinib |
GDSC1000 |
pan-cancer |
AAC |
-0.0058 |
0.9 |
| mRNA |
Axitinib |
GDSC1000 |
pan-cancer |
AAC |
0.0056 |
0.9 |